These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 39162874)
1. Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis. Habibi MA; Shad N; Mirjnani MS; Fasihi S; Sadeghi S; Karami S; Ahmadvand MH; Delbari P; Zare AH; Zare AH; Alavi SAN Neurosurg Rev; 2024 Aug; 47(1):445. PubMed ID: 39162874 [TBL] [Abstract][Full Text] [Related]
2. A Systematic Review and Meta-Analysis on the Effectiveness of Radiotherapy and Temozolomide Treatment With or Without Bevacizumab in Patients With Glioblastoma Multiforme. Yang F; Wang L; Zhao W; Wang S; Li J; Sun A; Wang M; Wang Z; Chen Z; Heng X Neurol India; 2024 Jul; 72(4):700-707. PubMed ID: 39216020 [TBL] [Abstract][Full Text] [Related]
3. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669 [TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic therapy for high-grade glioma. Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
6. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316 [TBL] [Abstract][Full Text] [Related]
7. Comment on - Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis. Chellapandian H; Jeyachandran S Neurosurg Rev; 2024 Oct; 47(1):708. PubMed ID: 39349713 [No Abstract] [Full Text] [Related]
8. The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis. Guo L; Li X; Chen Y; Liu R; Ren C; Du S Cancer Radiother; 2021 Apr; 25(2):182-190. PubMed ID: 33436285 [TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
10. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. Carter TC; Medina-Flores R; Lawler BE Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753 [TBL] [Abstract][Full Text] [Related]
11. Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis. Lu VM; Kerezoudis P; Brown DA; Burns TC; Quinones-Hinojosa A; Chaichana KL J Neurooncol; 2019 Jun; 143(2):177-185. PubMed ID: 30919157 [TBL] [Abstract][Full Text] [Related]
12. Surgery, radiotherapy and temozolomide in treating high-grade gliomas. Parlato C; Barbarisi M; Moraci M; Moraci A Front Biosci; 2006 May; 11():1280-3. PubMed ID: 16368514 [TBL] [Abstract][Full Text] [Related]
13. Temozolomide for high grade glioma. Hart MG; Garside R; Rogers G; Stein K; Grant R Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341 [TBL] [Abstract][Full Text] [Related]
14. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. Wang J; Huang Y; Zhao F; Chen J; He L; Liu Z; Pei Y; Wei Z; Li R; Ai P; Peng X J Neurooncol; 2022 Nov; 160(2):433-443. PubMed ID: 36357822 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282 [TBL] [Abstract][Full Text] [Related]
16. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272 [TBL] [Abstract][Full Text] [Related]
17. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490 [TBL] [Abstract][Full Text] [Related]
18. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
19. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]